Conexeu Sciences CNXU 深 滬
已收盤 07-31 16:00:00 美东时间
8.31
-0.520
-5.89%
華盛通- 最 高8.99
- 今 開8.89
- 成交量 16.58万股
- 最 低 8.26
- 昨 收 8.83
- 總市值 22.24万
- 52周最高 18.7915
- 市盈率 靜 --
- 換手率 0.62%
- 52周最低 7.1001
- 委 比 90.28%
- 總股本 2.68万
- 歷史最高 18.7915
- 量 比 1.46
- 振 幅 8.27%
- 歷史最低 7.1001
- 每 手 1
- 風險率 2.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pi...
07-09 20:16
190亿美元减肥热潮催生组织修复新需求，Conexeu瞄准市场空白
纳斯达克上市的临床前生物技术公司Conexeu Sciences（股票代码：CNXU）近日宣布，其CXU平台的临床前研究P.R.O.O.F阶段已完成，公司计划以...
07-08 03:13
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
Conexeu Sciences Inc. has completed its 12-month P.R.O.O.F study, supporting its entry into the $11 billion medical aesthetics market. The study demonstrated successful tissue restoration in both small and large volume models, meeting key benchmarks for injectable performance. Conexeu plans to submit a predicate-based 510(k) application for wound care in Q1 2027, with potential expansion into aesthetics. The growth of GLP-1 weight-loss drugs has ...
07-07 13:00
美股大行评级 | 阿斯麦获美银、富国上调目标价最高至2345美元；Needham上调美光科技目标价从500美元升至1550美元
今日重点评级关注：Baird：维持Regenxbio"跑赢大市"评级，目标价从27美元升至32美元；古根海姆：维持Tenax Therapeutics"买入"评级，目标价从34美元升至40美元
06-23 13:48
HC Wainwright & Co. Initiates Coverage On Conexeu Sciences with Buy Rating, Announces Price Target of $20
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Conexeu Sciences (NASDAQ:CNXU) with a Buy rating and announces Price Target of $20.
06-22 18:58
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
Issued on behalf of Conexeu Sciences Inc. Companies mentioned: Conexeu Sciences Inc. (NASDAQ: CNXU), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Evolus, Inc. (NASDAQ: EOLS), Bi...
05-22 22:31
